Description

Febentel 222: Fenbendazole for Worm Relief

If you have been prescribed Febendazole, you may notice different brand names available. This therapeutic option provides a strength of 222mg per dose unit. Patients can access this medicine through a regulated pharmacy supply with a valid prescription.

Composition

Active Ingredient

Fenbendazole 222mg

Manufacturer

WinLife Pharma

Variants Available

• Fenbentel 150
• Fenbentel 444
• Fenbentel 500
• Fenbentel 1000

Expiry

This product remains suitable for use for 24 to 36 months. Always check the expiry month and year on the packaging before use.

What is Febentel 222?

Febentel 222 is an anthelmintic (a medicine used to treat parasitic worm infections). It contains the active pharmaceutical ingredient Febendazole at a strength of 222mg. This product is a cost-effective option that meets strict pharmaceutical formulation standards. It delivers the same therapeutic effect as the UK reference brand, Panacur.

Febentel 222 vs Panacur Comparison

Feature	Febentel 222	Panacur
Active Ingredient (Salt)	Fenbendazole	Fenbendazole
Strength	222mg	Varies by formulation
Chemical Class	Benzimidazole	Benzimidazole
Mechanism of Action	Inhibits tubulin polymerisation	Inhibits tubulin polymerisation
Therapeutic Effect	Eradicates parasitic worms	Eradicates parasitic worms
Bioequivalence	Equivalent therapeutic profile	Standard UK reference profile

Mechanism of Action

Febendazole belongs to the benzimidazole chemical class. The active salt targetively binds to tubulin (a structural protein in parasite cells). This binding inhibits tubulin polymerisation (the process that forms the cellular skeleton of the worm). Consequently, the parasite cannot absorb glucose and dies.

Clinical Uses

• Treatment of gastrointestinal nematodes (parasitic roundworms).
• Eradication of cestodes (parasitic tapeworms).
• Management of systemic microfilarial infestations under specialist medical supervision.

Safety Information

Mild abdominal pain, nausea, and diarrhoea are among the commonly reported side effects. Serious side effects are rare but include leukopenia (a dangerous reduction in white blood cells) and hepatic dysfunction (liver impairment).

Safety Advice

Liver

Your doctor will monitor your liver enzymes. Febendazole undergoes hepatic metabolism and can exacerbate pre-existing liver impairment.

Kidney

Renal clearance removes metabolites from your system. Patients with kidney disease require careful dosage adjustment.

Alcohol

Avoid alcohol whilst taking this medication. Co-ingestion increases the metabolic strain on your liver cells.

Driving

Your ability to drive is not usually affected by this medicine. Driving should be avoided if dizziness or tiredness occurs.

Pregnancy

This medicine must not be used during pregnancy. Febendazole can cause harm to the developing foetus.

Breastfeeding

The active ingredient may be present in breast milk. Your healthcare provider will recommend alternative options.

Accessing Treatment Responsibly

You must obtain this medicine through authorised medical channels. Our verification process ensures you receive authentic products from WinLife Pharma. Every shipment utilises discreet packaging to preserve patient privacy and safety.

Frequently Asked Questions

Q: Is fenbendazole safe for human use?

A: Fenbendazole is considered safe when taken as prescribed by a doctor. This medicine should only be taken under the guidance of a registered healthcare professional. Always follow the dose and duration advised by your GP or specialist.

Q: What are the negative side effects of fenbendazole?

A: Nausea, stomach pain, vomiting, and diarrhoea may occur as side effects. In uncommon cases, a rise in liver enzyme levels may be observed. Contact your GP if any symptoms persist or worsen.

Conclusion

Febentel 222 is a competitively sourced veterinary anthelmintic option containing 222mg of Febendazole. It provides a reliable alternative to Panacur for targeted antiparasitic therapy. Always access your medicines safely through a regulated pharmacy supply.

References

• Defra.gov.uk: https://www.vmd.defra.gov.uk/productinformationdatabase/files/UKPAR_Documents/UKPAR_1059046.PDF
• VSDB: https://sitem.herts.ac.uk/aeru/vsdb/Reports/1758.htm

Medical Disclaimer

This content is for educational purposes only. This information does not replace professional medical advice, diagnosis, or treatment.